CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

IRVINE, Calif.--(BUSINESS WIRE)-- #CG0070--CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in NMIBC Unresponsive to Bacillus Calmette-Guerin

Click to view original post